IRWD News and Press, Ironwood Pharmaceuticals Inc.

2024-06-20 13:00:43 ET Summary Ironwood Pharmaceuticals, Inc. data from the phase 2 proof-of-concept study, using CNP-104 for the treatment of patients with primary biliary cholangitis, expected in Q3 of 2024. The global primary biliary cholangitis therapeutics market size is proj...

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 9:00 a.m. ET at the Marriott Marquis in New York City. A live webcast of I...

2024-05-22 07:30:10 ET Wells Fargo analyst issues OVERWEIGHT recommendation for IRWD on May 22, 2024 05:13AM ET. The previous analyst recommendation was Overweight. IRWD was trading at $6.78 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

2024-05-22 07:00:07 ET Mohit Bansal from Wells Fargo issued a price target of $14.00 for IRWD on 2024-05-22 05:13:00. The adjusted price target was set to $14.00. At the time of the announcement, IRWD was trading at $6.78. The overall price target consensus is at $16.00 ...

– New data highlight both stoma and colon-in-continuity (CIC) patients drove the positive primary endpoint with significant relative change from baseline in weekly parenteral support (PS) volume reduction at week 24 – – Additional secondary endpoints show significant ...

2024-05-09 17:54:02 ET Ironwood Pharmaceuticals, Inc. (IRWD) Q1 2024 Earnings Conference Call May 09, 2024 08:30 AM ET Company Participants Matt Roache - Director of IR Tom McCourt - CEO Mike Shetzline - Chief Medical Officer Sravan Emany - CFO Conferen...

2024-05-09 07:20:25 ET More on Ironwood Pharmaceuticals Ironwood Pharmaceuticals, Inc. (IRWD) Q4 2023 Earnings Call Transcript Ironwood Pharmaceuticals Q1 2024 Earnings Preview Ironwood plunges nearly 40% after SBS trial misses secondary goals Seeking Alpha&#...

AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...

– Reported positive topline results from global Phase III STARS trial of once-weekly apraglutide in adults with short bowel syndrome with intestinal failure (SBS-IF) – – Reported positive results from Phase II exploratory STARGAZE trial of apraglutide in patients with...

2024-05-08 11:21:03 ET More on Ironwood Pharmaceuticals Ironwood Pharmaceuticals, Inc. (IRWD) Q4 2023 Earnings Call Transcript Ironwood plunges nearly 40% after SBS trial misses secondary goals KLIC, IRWD and GRFS among pre-market losers Seeking Alpha’...